Genomic Evidence on Antihypertensive Drug Targets and Oral Disease Outcomes
Aiswarya Puzhakkara Chennas, Ignacio Leiva‐Escobar, Stefan Lars Reckelkamm, Birte Holtfreter, Thomas Kocher, Sebastian‐Edgar Baumeister, Michael Nolde, Zoheir Alayash · 2026
Read Genomic Evidence on Antihypertensive Drug Targets and Oral Disease Outcomes by Aiswarya Puzhakkara Chennas, Ignacio Leiva‐Escobar, Stefan Lars Reckelkamm, Birte Holtfreter, Thomas Kocher, Sebastian‐Edgar Baumeister, Michael Nolde, Zoheir Alayash (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13471875.txt.
Description
Aiswarya Puzhakkara Chennas and colleagues use genetics in 2026 to ask whether blood pressure drugs change the risk of gum disease and tooth decay. Direct trials would be slow and confounded, so the team used inherited variants near each drug target gene as stand ins for lifelong drug action. Twelve antihypertensive classes were instrumented this way, drawing on huge blood pressure genome studies.
One signal survived correction for many tests: genetic mimicry of diazoxide, acting through a potassium channel gene, raised the odds of chronic gum disease slightly per unit of lowered pressure. The link held after removing variants tied to diabetes, a possible side path. No other drug class showed an association with gum disease, and none with tooth decay. Checks for shared causal variants accompanied the main analysis.
Catalog record
| CREATOR | Aiswarya Puzhakkara Chennas, Ignacio Leiva‐Escobar, Stefan Lars Reckelkamm, Birte Holtfreter, Thomas Kocher, Sebastian‐Edgar Baumeister, Michael Nolde, Zoheir Alayash |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 56218 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |